{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Tiotropium+Placebo&page=2",
    "query": {
      "intervention": "Tiotropium Placebo",
      "page": 2
    },
    "page_size": 10
  },
  "pagination": {
    "page": 2,
    "page_size": 10,
    "total_count": 10,
    "total_pages": 1,
    "next_page_url": null,
    "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Tiotropium+Placebo&page=1&page_size=10"
  },
  "source": "remote",
  "last_synced_at": "2026-09-28T20:00:37.700Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT03478696",
      "title": "A Randomized Study, Comparing Fluticasone Furoate/Umeclidinium/Vilanterol (FF/UMEC /VI) Single Inhaler Triple Therapy, Versus Multiple Inhaler Therapy (Budesonide/Formoterol Plus Tiotropium) in Subjects With Chronic Obstructive Pulmonary Disease (COPD)",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE4"
      ],
      "conditions": [
        "Pulmonary Disease, Chronic Obstructive"
      ],
      "interventions": [
        {
          "name": "budesonide/formoterol",
          "type": "DRUG"
        },
        {
          "name": "albuterol/salbutamol",
          "type": "DRUG"
        },
        {
          "name": "FF/UMEC/VI",
          "type": "DRUG"
        },
        {
          "name": "Placebo to match budesonide/formoterol",
          "type": "DRUG"
        },
        {
          "name": "tiotropium",
          "type": "DRUG"
        },
        {
          "name": "Placebo to match FF/UMEC/VI",
          "type": "DRUG"
        },
        {
          "name": "placebo to match tiotropium",
          "type": "DRUG"
        },
        {
          "name": "ELLIPTA",
          "type": "DEVICE"
        },
        {
          "name": "MDI",
          "type": "DEVICE"
        },
        {
          "name": "HandiHaler",
          "type": "DEVICE"
        }
      ],
      "intervention_types": [
        "DRUG",
        "DEVICE"
      ],
      "sponsor": "GlaxoSmithKline",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "40 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "40 Years and older"
      },
      "enrollment_count": 732,
      "start_date": "2018-06-25",
      "completion_date": "2019-03-18",
      "has_results": true,
      "last_update_posted_date": "2020-10-28",
      "last_synced_at": "2026-09-28T20:00:37.700Z",
      "location_count": 42,
      "location_summary": "Mobile, Alabama • Bakersfield, California • Sacramento, California + 35 more",
      "locations": [
        {
          "city": "Mobile",
          "state": "Alabama"
        },
        {
          "city": "Bakersfield",
          "state": "California"
        },
        {
          "city": "Sacramento",
          "state": "California"
        },
        {
          "city": "San Diego",
          "state": "California"
        },
        {
          "city": "Westminster",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03478696"
    },
    {
      "nct_id": "NCT03937479",
      "title": "Study Investigating the Effect of 4 Doses of RPL554 Given in Addition to Tiotropium to Patients With COPD",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "COPD"
      ],
      "interventions": [
        {
          "name": "Ensifentrine (formerly RPL554) 0.375 mg twice daily plus placebo, in addition to tiotropium",
          "type": "DRUG"
        },
        {
          "name": "Ensifentrine (formerly RPL554) 0.75 mg twice daily plus placebo, in addition to tiotropium",
          "type": "DRUG"
        },
        {
          "name": "Ensifentrine (formerly RPL554) 1.5 mg twice daily plus placebo, in addition to tiotropium",
          "type": "DRUG"
        },
        {
          "name": "Ensifentrine (formerly RPL554) 3.0 mg twice daily plus placebo, in addition to tiotropium",
          "type": "DRUG"
        },
        {
          "name": "Ensifentrine (formerly RPL554) placebo twice daily, in addition to tiotropium",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Verona Pharma, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "40 Years",
        "maximum_age": "80 Years",
        "sex": "ALL",
        "summary": "40 Years to 80 Years"
      },
      "enrollment_count": 416,
      "start_date": "2019-05-01",
      "completion_date": "2019-11-15",
      "has_results": true,
      "last_update_posted_date": "2020-11-20",
      "last_synced_at": "2026-09-28T20:00:37.700Z",
      "location_count": 50,
      "location_summary": "Anniston, Alabama • Fullerton, California • Los Angeles, California + 44 more",
      "locations": [
        {
          "city": "Anniston",
          "state": "Alabama"
        },
        {
          "city": "Fullerton",
          "state": "California"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Lafayette",
          "state": "Colorado"
        },
        {
          "city": "Brandon",
          "state": "Florida"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03937479"
    },
    {
      "nct_id": "NCT01202188",
      "title": "A Study to Assess the Efficacy, Safety and Tolerability of Once-daily (q.d.) QVA149 in Patients With Moderate to Severe Chronic Obstructive Pulmonary Disease (COPD)",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Chronic Obstructive Pulmonary Disease (COPD)"
      ],
      "interventions": [
        {
          "name": "indacaterol and glycopyrronium (QVA149)",
          "type": "DRUG"
        },
        {
          "name": "glycopyrronium (NVA237)",
          "type": "DRUG"
        },
        {
          "name": "indacaterol (QAB149)",
          "type": "DRUG"
        },
        {
          "name": "tiotropium",
          "type": "DRUG"
        },
        {
          "name": "placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Novartis Pharmaceuticals",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "40 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "40 Years and older"
      },
      "enrollment_count": 2144,
      "start_date": "2010-09",
      "completion_date": "2012-03",
      "has_results": true,
      "last_update_posted_date": "2013-09-09",
      "last_synced_at": "2026-09-28T20:00:37.700Z",
      "location_count": 14,
      "location_summary": "Fullerton, California • Riverside, California • St. Petersburg, Florida + 11 more",
      "locations": [
        {
          "city": "Fullerton",
          "state": "California"
        },
        {
          "city": "Riverside",
          "state": "California"
        },
        {
          "city": "St. Petersburg",
          "state": "Florida"
        },
        {
          "city": "Troy",
          "state": "Michigan"
        },
        {
          "city": "Minneapolis",
          "state": "Minnesota"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01202188"
    },
    {
      "nct_id": "NCT01179347",
      "title": "Tiotropium Bromide in Cystic Fibrosis",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Cystic Fibrosis"
      ],
      "interventions": [
        {
          "name": "tiotropium Respimat® inhaler",
          "type": "DRUG"
        },
        {
          "name": "Placebo Respimat® inhaler",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Boehringer Ingelheim",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": null,
        "maximum_age": null,
        "sex": "ALL",
        "summary": "Not listed"
      },
      "enrollment_count": 464,
      "start_date": "2010-09",
      "completion_date": null,
      "has_results": true,
      "last_update_posted_date": "2013-12-24",
      "last_synced_at": "2026-09-28T20:00:37.700Z",
      "location_count": 15,
      "location_summary": "Tuscon, Arizona • San Diego, California • Jacksonville, Florida + 10 more",
      "locations": [
        {
          "city": "Tuscon",
          "state": "Arizona"
        },
        {
          "city": "San Diego",
          "state": "California"
        },
        {
          "city": "Jacksonville",
          "state": "Florida"
        },
        {
          "city": "Orlando",
          "state": "Florida"
        },
        {
          "city": "Orlando",
          "state": "Florida"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01179347"
    },
    {
      "nct_id": "NCT01126437",
      "title": "Comparison of Tiotropium in the HandiHaler Versus the Respimat in Chronic Obstructive Pulmonary Disease",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Pulmonary Disease, Chronic Obstructive"
      ],
      "interventions": [
        {
          "name": "tiotropium 18 mcg",
          "type": "DRUG"
        },
        {
          "name": "tiotropium 1.25 mcg (2 actuations/day)",
          "type": "DRUG"
        },
        {
          "name": "tiotropium 2.5 mcg (2 actuations/day)",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Boehringer Ingelheim",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "40 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "40 Years and older"
      },
      "enrollment_count": 17183,
      "start_date": "2010-05",
      "completion_date": "2013-05",
      "has_results": true,
      "last_update_posted_date": "2014-06-20",
      "last_synced_at": "2026-09-28T20:00:37.700Z",
      "location_count": 303,
      "location_summary": "Athens, Alabama • Birmingham, Alabama • Florence, Alabama + 243 more",
      "locations": [
        {
          "city": "Athens",
          "state": "Alabama"
        },
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Birmingham",
          "state": "Alabama"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01126437"
    },
    {
      "nct_id": "NCT01533922",
      "title": "Effect on Exercise Endurance and Lung Hyperinflation of Tiotropium + Olodaterol in COPD Patients",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Pulmonary Disease, Chronic Obstructive"
      ],
      "interventions": [
        {
          "name": "Placebo",
          "type": "DRUG"
        },
        {
          "name": "Tiotropium",
          "type": "DRUG"
        },
        {
          "name": "Olodaterol",
          "type": "DRUG"
        },
        {
          "name": "Tiotropium + Olodaterol",
          "type": "DRUG"
        },
        {
          "name": "Respimat",
          "type": "DEVICE"
        }
      ],
      "intervention_types": [
        "DRUG",
        "DEVICE"
      ],
      "sponsor": "Boehringer Ingelheim",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "40 Years",
        "maximum_age": "75 Years",
        "sex": "ALL",
        "summary": "40 Years to 75 Years"
      },
      "enrollment_count": 295,
      "start_date": "2012-03",
      "completion_date": "2013-11",
      "has_results": true,
      "last_update_posted_date": "2015-09-15",
      "last_synced_at": "2026-09-28T20:00:37.700Z",
      "location_count": 8,
      "location_summary": "Torrance, California • Hartford, Connecticut • Livonia, Michigan + 5 more",
      "locations": [
        {
          "city": "Torrance",
          "state": "California"
        },
        {
          "city": "Hartford",
          "state": "Connecticut"
        },
        {
          "city": "Livonia",
          "state": "Michigan"
        },
        {
          "city": "Pittsburgh",
          "state": "Pennsylvania"
        },
        {
          "city": "Easley",
          "state": "South Carolina"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01533922"
    },
    {
      "nct_id": "NCT01172808",
      "title": "Evaluation of Tiotropium 2.5 and 5 mcg Once Daily Delivered Via the Respimat® Inhaler Compared to Placebo and Salmeterol HydroFluoroAlkane (HFA) Metered Dose Inhaler (MDI) (50 mcg Twice Daily) in Patient With Moderate Persistent Asthma I",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Asthma"
      ],
      "interventions": [
        {
          "name": "Placebo",
          "type": "DRUG"
        },
        {
          "name": "tiotropium Respimat® low dose",
          "type": "DRUG"
        },
        {
          "name": "tiotropium Respimat® high dose",
          "type": "DRUG"
        },
        {
          "name": "50 mcg salmeterol HFA MDI",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Boehringer Ingelheim",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "75 Years",
        "sex": "ALL",
        "summary": "18 Years to 75 Years"
      },
      "enrollment_count": 1071,
      "start_date": "2010-08",
      "completion_date": "2012-11",
      "has_results": true,
      "last_update_posted_date": "2014-06-09",
      "last_synced_at": "2026-09-28T20:00:37.700Z",
      "location_count": 21,
      "location_summary": "Huntington Beach, California • Mission Viejo, California • San Diego, California + 17 more",
      "locations": [
        {
          "city": "Huntington Beach",
          "state": "California"
        },
        {
          "city": "Mission Viejo",
          "state": "California"
        },
        {
          "city": "San Diego",
          "state": "California"
        },
        {
          "city": "Wheat Ridge",
          "state": "Colorado"
        },
        {
          "city": "Coeur d'Alene",
          "state": "Idaho"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01172808"
    },
    {
      "nct_id": "NCT00668772",
      "title": "Tiotropium/Salmeterol Inhalation Powder in COPD",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Pulmonary Disease, Chronic Obstructive"
      ],
      "interventions": [
        {
          "name": "Tiotropium/Salmeterol",
          "type": "DRUG"
        },
        {
          "name": "Salmeterol",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        },
        {
          "name": "Tiotropium",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Boehringer Ingelheim",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "40 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "40 Years and older"
      },
      "enrollment_count": 207,
      "start_date": "2008-04-15",
      "completion_date": "2008-11-21",
      "has_results": true,
      "last_update_posted_date": "2026-07-16",
      "last_synced_at": "2026-09-28T20:00:37.700Z",
      "location_count": 16,
      "location_summary": "Anniston, Alabama • Mobile, Alabama • Clearwater, Florida + 10 more",
      "locations": [
        {
          "city": "Anniston",
          "state": "Alabama"
        },
        {
          "city": "Mobile",
          "state": "Alabama"
        },
        {
          "city": "Clearwater",
          "state": "Florida"
        },
        {
          "city": "Tampa",
          "state": "Florida"
        },
        {
          "city": "Tampa",
          "state": "Florida"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00668772"
    },
    {
      "nct_id": "NCT01543919",
      "title": "Study To Evaluate The Efficacy And Safety Of PH-797804 For 12 Weeks In Adults With Moderate To Severe Chronic Obstructive Pulmonary Disease (COPD) On A Background Of Tiotropium Bromide",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Pulmonary Disease, Chronic Obstructive"
      ],
      "interventions": [
        {
          "name": "PH-797804",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Pfizer",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "40 Years",
        "maximum_age": "80 Years",
        "sex": "ALL",
        "summary": "40 Years to 80 Years"
      },
      "enrollment_count": 730,
      "start_date": "2012-04",
      "completion_date": "2013-09",
      "has_results": false,
      "last_update_posted_date": "2014-10-27",
      "last_synced_at": "2026-09-28T20:00:37.700Z",
      "location_count": 45,
      "location_summary": "Birmingham, Alabama • Jasper, Alabama • Phoenix, Arizona + 33 more",
      "locations": [
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Jasper",
          "state": "Alabama"
        },
        {
          "city": "Phoenix",
          "state": "Arizona"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01543919"
    },
    {
      "nct_id": "NCT00776984",
      "title": "Evaluation of Tiotropium 5 µg/Day Delivered Via the Respimat® Inhaler Over 48 Weeks in Patients With Severe Persistent Asthma on Top of Usual Care (Study II)",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Asthma"
      ],
      "interventions": [
        {
          "name": "tiotropium 5mcg/day",
          "type": "DRUG"
        },
        {
          "name": "placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Boehringer Ingelheim",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "75 Years",
        "sex": "ALL",
        "summary": "18 Years to 75 Years"
      },
      "enrollment_count": 453,
      "start_date": "2008-10",
      "completion_date": null,
      "has_results": true,
      "last_update_posted_date": "2014-09-10",
      "last_synced_at": "2026-09-28T20:00:37.700Z",
      "location_count": 18,
      "location_summary": "Fountain Valley, California • Fresno, California • Stockton, California + 15 more",
      "locations": [
        {
          "city": "Fountain Valley",
          "state": "California"
        },
        {
          "city": "Fresno",
          "state": "California"
        },
        {
          "city": "Stockton",
          "state": "California"
        },
        {
          "city": "Waterbury",
          "state": "Connecticut"
        },
        {
          "city": "Pensacola",
          "state": "Florida"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00776984"
    }
  ]
}